Quote:

---

The protocol has been published at clinicaltrials.gov. I noticed that they did not exclude patients with the Delta 32 mutation (single or double allele). I wonder if this is a mistake -- ? Would be happy to if anyone with a better understanding of Leron's MOA eased my mind.

---

One of the inclusion criteria is expression of CCR5 on the tumor so patients with double allele deletion would be excluded but not single allele.